BOLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BOLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-12-13), Bolt Biotherapeutics's 6-Month Price Index is 0.69.
For the Biotechnology subindustry, Bolt Biotherapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
6-Month Price Index is calculated as following:
6-Month Price Index | = | Current Share Price | / | Share Price 6-Months Ago |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (NAS:BOLT) 6-Month Price Index Explanation
Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.
The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.
Thank you for viewing the detailed overview of Bolt Biotherapeutics's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.
William P. Quinn | officer: Chief Financial Officer | SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Edgar Engleman | director | 575 HIGH STREET, STE 201, PALO ALTO CA 94301 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Laura Berner | director | C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Brian O'callaghan | director | 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
Frank D. Lee | director | C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472 |
Kathleen Laporte | director | |
Miller Richard A Md | director | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Mahendra Shah | director | 2250 HOLCOMBE BLVD, HOUSTON TX 77030 |
Grant Yonehiro | officer: Chief Business Officer | C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Randall C Schatzman | director, officer: Chief Executive Officer | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
David Dornan | officer: Chief Scientific Officer | C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Edith A. Perez | officer: Chief Medical Officer | C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063 |
From GuruFocus
By Marketwired • 08-28-2024
By Marketwired • 08-21-2024
By PRNewswire • 08-26-2024
By Marketwired • 08-25-2024
By PRNewswire • 08-24-2024
By PRNewswire • 08-31-2024
By PRNewswire • 08-30-2024
By Marketwired • 09-01-2024
By PRNewswire • 08-21-2024
By GuruFocus News • 10-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.